We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+1.91%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.7B
AUM Growth
+$101M
Cap. Flow
+$158M
Cap. Flow %
1.07%
Top 10 Hldgs %
22.11%
Holding
946
New
64
Increased
332
Reduced
304
Closed
69

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$57.5M
2
AZN icon
AstraZeneca
AZN
+$44.9M
3
ADSK icon
Autodesk
ADSK
+$43.5M
4
MELI icon
Mercado Libre
MELI
+$40.7M
5
AMGN icon
Amgen
AMGN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$92.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$88M
3
BABA icon
Alibaba
BABA
+$73.8M
4
MRK icon
Merck
MRK
+$49.8M
5
MXIM
Maxim Integrated Products
MXIM
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 32.09%
2 Technology 24.53%
3 Financials 9.08%
4 Communication Services 8.24%
5 Consumer Discretionary 7.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNR icon
876
Pentair
PNR
$10.8B
– –
-17
Closed -$1K
RIOT icon
877
Riot Platforms
RIOT
$8.03B
– –
-5,840
Closed -$220K
ROL icon
878
Rollins
ROL
$18.8B
– –
-39,835
Closed -$1.36M
SAP icon
879
SAP
SAP
$209B
– –
-10
Closed -$1K
SPRY icon
880
ARS Pharmaceuticals
SPRY
$563M
– –
-196,557
Closed -$6.07M
STRO icon
881
Sutro Biopharma
STRO
$393M
– –
-36,621
Closed -$6.81M
TBPH icon
882
Theravance Biopharma
TBPH
$875M
– –
-475,696
Closed -$6.91M
TCOM icon
883
Trip.com Group
TCOM
$28.5B
– –
-62,910
Closed -$2.23M
TMHC icon
884
Taylor Morrison
TMHC
– –
-124,810
Closed -$3.3M
TTD icon
885
Trade Desk
TTD
$8.89B
– –
-2,860
Closed -$221K
UDR icon
886
UDR
UDR
$12.7B
– –
-6,499
Closed -$318K
VALE icon
887
Vale
VALE
$62.6B
– –
-12,775
Closed -$291K
VIPS icon
888
Vipshop
VIPS
$7.13B
– –
-1,513,624
Closed -$30.4M
XPO icon
889
XPO
XPO
$24B
– –
-17,476
Closed -$845K
ZTO icon
890
ZTO Express
ZTO
$18.2B
– –
-50,000
Closed -$1.52M
ZYME icon
891
Zymeworks
ZYME
$1.66B
– –
-473,124
Closed -$16.4M
QCLS
892
Q/C Technologies Inc
QCLS
$22.3M
– –
-6
Closed -$114K
GAP
893
The Gap Inc
GAP
$7.28B
– –
-10,937
Closed -$368K
RNTX
894
Rein Therapeutics
RNTX
$66.9M
– –
-1,128
Closed -$28K
ACHL
895
DELISTED
Achilles Therapeutics
ACHL
– –
-161,624
Closed -$1.58M
BCEL
896
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-373,706
Closed -$3.18M
TCRR
897
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-934,551
Closed -$15.3M
CIXX
898
DELISTED
CI Financial Corp.
CIXX
– –
-18,696
Closed -$343K
EAR
899
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-495
Closed -$395K
ABMD
900
DELISTED
Abiomed Inc
ABMD
– –
-764
Closed -$238K
33 34 35
36
37

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2021 Portfolio in Review

As of Q3 2021, Candriam SCA held 946 positions worth $14.7B, up 0.69% from $14.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA's Q3 2021 filing shows 64 new, 332 increased, 304 reduced and 69 closed positions. Its largest new stake was FIVE9: 86,075 shares worth $13.7M. The largest sale was Alexion Pharmaceuticals, an estimated $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q3 2021 buy was FIVE9: 86,075 shares worth $13.7M.
  • Candriam SCA added most to Johnson & Johnson in Q3 2021, an estimated $57.5M increase.
  • Candriam SCA's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $88M.
  • Candriam SCA fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $92.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $14.7B portfolio in Q3 2021.
  • Candriam SCA opened 64 new positions and closed 69 in Q3 2021.
  • Candriam SCA's portfolio value rose 0.69% quarter-over-quarter to $14.7B.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.